Home › Calculator › KMDA Dividend Calculator 2026
KMDA Dividend DRIP Calculator 2026
3.44% YieldHealthcareKamada Ltd. · NASDAQ
Price: $7.27 · Annual div: $0.25/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When KMDA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your KMDA snowball 📈
$10,000 in KMDA → $19.0K in 10 years · $37.00/month
About Kamada Ltd. (KMDA) — Dividend Analysis 2026
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Compare KMDA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full KMDA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open KMDA position with:
🌍 KMDA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold KMDA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.44% | 0.64% | $344 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.92% | 0.12% | $292 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.75% | -0.05% | $275 / yr |
| 🇬🇧 UK ISA | 0% | 3.44% | 0.64% | $344 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.14% | 0.34% | $314 / yr |
| 🇨🇦 TFSA | 0% | 3.44% | 0.64% | $344 / yr |
| 🇨🇦 CA Taxable | 25% | 2.58% | -0.22% | $258 / yr |
| 🇦🇺 Super (pension) | 15% | 2.92% | 0.12% | $292 / yr |
| 🇦🇺 AU Taxable | 30% | 2.41% | -0.39% | $241 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.53% | -0.27% | $253 / yr |
| 🇫🇷 FR Taxable | 30% | 2.41% | -0.39% | $241 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 KMDA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.25/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 KMDA Dividend Payment Schedule
KMDA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 KMDA vs Healthcare Benchmarks
How KMDA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for KMDA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ KMDA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-08-26 | 10,000 | $6.25 | $62.5K | ||
| F-InKind | 2026-08-26 | 2,776 | $8.58 | $23.8K | ||
| M-Exempt | 2026-08-26 | 10,000 | $6.25 | $62.5K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K | ||
| A-Award | 2026-08-05 | 30,000 | $7.52 | $225.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where KMDA earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the KMDA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Kamada Ltd. (KMDA) is currently trading at $7.27, 20% below its 52-week high. The current dividend yield is 3.44% based on an annual payout of $0.25 per share.
KMDA (Kamada Ltd.) — 3.44% Dividend Yield Analysis
Kamada Ltd. (KMDA) is a healthcare stock currently trading at $7.27 with a dividend yield of 3.44%. The company pays an annual dividend of $0.25 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest KMDA News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.